Skip to main content

TNF inhibitor

RheumNow Podcast – Lupus Delights (9.18.20)

Sep 18, 2020

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

Read Article
Retrospective cohort study of 213 IMID patients, 36.2% tested positive for COVID-19, who had no greater risk of hospitalized or ventilation and immunosuppressive use was not shown to worsened the course of disease (TNFi decreased risk of hospitalization) https://t.c

Dr. John Cush RheumNow ( View Tweet)

Sep 16, 2020
Discontinuing TNFi before wk 20 is feasible in RA and JIA pregnancy with well- controlled Dz. OTIS study of 490 women compared 25% who D/C TNFi before wk 20 vs 41% taking TNFi after wk 20. D/C TNF not assoc w/ clinical worsening in the 3rd trimester.

Dr. John Cush RheumNow ( View Tweet)

Sep 12, 2020
Systematic review of Paternal DMARD exposure prior to pregnancy shows no firm evidence of harm with TNFi, ABA, RTX, azathioprine, cyclosporine, HCQ, leflunomide, MTX or mycophenolate mofetil.

Dr. John Cush RheumNow ( View Tweet)

Sep 11, 2020

ICYMI - 11 Pearls for Pregnancy Management in Rheumatoid Arthritis

Sep 09, 2020

Rheumatoid arthritis affects women in their child-bearing years and many will face the issue of pregnancy and RA management at some point. Here are11 considerations for those managing RA patients who wish to become pregnant.



Read Article

RheumNow Podcast – To Celiac Test or Not? (9.4.20)

Sep 04, 2020

Dr Jack Cush reviews the news, journal articles and takes a few Back Talk questions this week:

Read Article
RheumNow Podcast is Up! Rheum Lives Matter. More about social change, HCQ, JAKs & skin, growing cartilage, FM exercise. Watch it here>https://t.co/LLvADsDJ5O or listen to the Podcast here>https://t.co/pCXzaJUS9s

Dr. John Cush RheumNow ( View Tweet)

Aug 29, 2020
UK safety reminder that Baricitinib (Olumiant) has an increased risk of diverticulitis (incidence rate 0.16 per 100PY), esp. in those taking Steroids or NSAIDs. https://t.co/IfcV03e1p7

Dr. John Cush RheumNow ( View Tweet)

Aug 28, 2020
Mayo case controlled study of 212 autoimmune pts - half w/ CNS inflamm dz and half without.

Dr. John Cush RheumNow ( View Tweet)

Aug 24, 2020
Responses to switching TNFi in SpA go down w/ the 2nd TNFi. 1st TNFi @ 3 mos ASAS CII 51%; 2nd TNFi 41%; BASDAI @6 mo, 1st 46%, 2nd TNFi 33%.
Dr. John Cush RheumNow ( View Tweet)
Aug 24, 2020

Selective Biologic Responses in Seropositive RA

Aug 20, 2020

The Journal of Rheuatology reports a pooled analysis of patients from 16 observational RA registries that examined the association between seropositivity (RF or ACPA) with biologic DMARDs responses; they showed better clinical responses when seropositive RA patients receive abatacept (ABA) or

Read Article

RheumNow Podcast – The Bad News That’s Fit to Print (8.21.20)

Aug 20, 2020

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.

Read Article
Study of 2 Canadian centers finds amongst 2095 patients taking biologics for #Psoriasis, 23 (1.1%) stopped their biologic for "COVID-19 related concerns". 5/23 restarted biologic for PSO flares.

Dr. John Cush RheumNow ( View Tweet)

Aug 20, 2020
Forward study of 18,754 RA patients who experienced 1,801 CVD events and found CVD risk reduction with TNFi (HR 0.82 [95% CI 0.72-0.94]) and abatacept (HR 0.50 [95% CI 0.30-0.83]) compared to csDMARDs over & above MTX alone (use vs.

Dr. John Cush RheumNow ( View Tweet)

Aug 19, 2020

Upadacitinib is Superior to Methotrexate in Early RA

Aug 17, 2020

In a head-to-head trial against methotrexate, JAK1 inhibition with upadacitinib was shown to be more effective in early, DMARD-naive RA patients. Here are the primary results.

Read Article

RheumNow Podcast - The SARS-CoV-2 Update (8-14-20)

Aug 14, 2020

Dr. Jack Cush updates the news and journal articles from the past week on RheumNow.com, with information on enthesitis, nr-Ax-SpA, UAB, Blockbuster Rheum Drugs and use of ACE inhibitors.

Read Article

Rheumatic Diseases, Drugs and COVID-19 Guidelines

Aug 13, 2020

Several recent publications have focused on the risk and outcomes of rheumatic disease (RDD) and autoimmune patients who become infected with SARs-CoV-2.

Read Article

Infliximab Use Near Surgery is Safe

Aug 11, 2020

Risk factors for perioperative infections include age, comorbidity, rheumatoid arthritis and steroids to name a few; whether concurrent use of TNF inhibitor (TNFI) therapy adds to this risk has been debated. In a study of elderly patients receiving infliximab infusions, infliximab use prior to

Read Article

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

GI Perforations with Tocilizumab Greater than Other Biologics

Jul 27, 2020

A study from a Swedish population shows the real-world risk of gastrointestinal (GI) perforations in rheumatoid arthritis (RA) patients taking biologics finds that the risk was greatest in RA patients taking tocilizumab (TCZ), compared with RA patient taking tumour necrosis factor inhibitors (

Read Article
The RheumNow Podcast is up - COVID-19 Responds to Steroids & TCZ, statin myopathy, Lung Dz in AOSD, TNFi & Liver, IL-23 in Psoriasis.

Dr. John Cush RheumNow ( View Tweet)

Jul 24, 2020
CORRONA Registry shows no difference in 1 year outcomes when RA patients are given 1st line TNF inhibitors compared to 1st line non-TNF biologics (ABA, TCZ, RTX, anakinra, TOFA: thus supporting current RA guidelines, recommending individualised care https://t.co/Y

Dr. John Cush RheumNow ( View Tweet)

Jul 24, 2020
Literature review suggests that TNF inhibitors are safe to use in NAFLD and may show a beneficial effect on hepatic tissue. TNFi should be prescribed with caution in patients w/ cirrhosis as the data are conflicting. https://t.co/uynkNNCxdt

Dr. John Cush RheumNow ( View Tweet)

Jul 22, 2020

Risankizumab Outduels Secukinumab in Psoriasis

Jul 20, 2020

The IMMerge trial has demonstrated the superiority of interleukin (IL)‐23 over IL-17A inhibition adults with plaque psoriasis.



This multicenter, phase 3, open‐label study enrolled 327 adult patients with chronic, moderate‐to‐severe plaque psoriasis who were randomised risankizumab (

Read Article
Single center retrospective Korean study of 1280 Ankylosing Spondylitis patients (595 exposed to TNFi) showed that TNFi was associated with significantly decreased Xray change rate (mSASSS) (β=−0.112, p=0.004). https://t.co/W4j0Ckt0R2

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2020
×